How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies?

There is no fulltext present in this item.

Title:	How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies?
Author(s):	Kamburova, E.G.; Wisse, B.W.; Joosten, I. ; Allebes, W.A. ; Meer, A. van der ; Hilbrands, L.B. ; Baas, M.C. ; Spierings, E.; Hack, C.E.; Reekum, F.E. van; Zuilen, A.D. van; Verhaar, M.; Bots, M.L.; Drop, A.C.; Plaisier, L.; Seelen, M.A.; Sanders, J.S.; Hepkema, B.G.; Lambeck, A.J.A.; Bungener, L.B.; Roozendaal, C.; Tilanus, M.G.; Vanderlocht, J.; Voorter, C.E.M.; Wieten, L.; Duijnhoven, E.M. van; Gelens, M.; Christiaans, M.H.; Ittersum, F.J. van; Nurmohamed, A.; Lardy, N.M.; Swelsen, W.; Pant, K.A. van der; Weerd, N.C. van der; Berge, I.J. Ten; Bemelman, F.J.; Hoitsma, A.; Boog, P.J. van der; Fijter, J.W. de; Betjes, M.G.; Heidt, S.; Roelen, D.L.; Claas, F.H.; Otten, H.G.
Publication year:	2016
Source:	Hla, vol. 88, iss. 3, (2016), pp. 110-119
ISSN:	2059-2302
DOI:	https://doi.org/10.1111/tan.12860
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/172693
Display more details
Subject:	Radboudumc 0: Other Research RIMLS: Radboud Institute for Molecular Life Sciences Radboudumc 11: Renal disorders RIHS: Radboud Institute for Health Sciences Radboudumc 5: Inflammatory diseases RIMLS: Radboud Institute for Molecular Life Sciences
Organization:	Paediatrics - OUD tm 2017 Laboratory Medicine Nephrology
Journal title:	Hla
Volume:	vol. 88
Issue:	iss. 3
Page start:	p. 110
Page end:	p. 119
Abstract:	Solid-phase multiplex-bead assays are widely used in transplantation to detect anti-human leukocyte antigen (HLA) antibodies. These assays enable high resolution detection of low levels of HLA antibodies. However, multiplex-bead assays are costly and yield variable measurements that limit the comparison of results between laboratories. In the context of a Dutch national Consortium study we aimed to determine the inter-assay and inter-machine variability of multiplex-bead assays, and we assessed how to reduce the assay reagents costs. Fifteen sera containing a variety of HLA antibodies were used yielding in total 7092 median fluorescence intensities (MFI) values. The inter-assay and inter-machine mean absolute relative differences (MARD) of the screening assay were 12% and 13%, respectively. The single antigen bead (SAB) inter-assay MARD was comparable, but showed a higher lot-to-lot variability. Reduction of screening assay reagents to 50% or 40% of manufacturers' recommendations resulted in MFI values comparable to 100% of the reagents, with an MARD of 12% or 14%, respectively. The MARD of the 50% and 40% SAB assay reagent reductions were 11% and 22%, respectively. From this study, we conclude that the reagents can be reliably reduced at least to 50% of manufacturers' recommendations with virtually no differences in HLA antibody assignments.